Psoriasis Scalp Treatment

Description

The product is identified by the SPL code 34089-3. No specific description details are provided in the text.

Uses and Indications

This drug is indicated for the treatment of scalp fungal infections, specifically targeting conditions such as ringworm on the scalp. It is effective in providing relief from symptoms associated with folliculitis affecting the scalp. Additionally, this drug alleviates discomfort caused by lichen planus that involves the scalp.

Dosage and Administration

Healthcare professionals are advised to shake the Folliculitis Scalp Spray well before use. The spray should be applied to the affected area 2 to 3 times daily. It is imperative to avoid contact with the eyes and mucous membranes during application to prevent irritation or adverse effects.

Contraindications

There are no contraindications associated with the use of this product. It is not classified as a controlled substance, and there are no identified risks of abuse, misuse, or dependence. Additionally, there are no specific instructions indicating that the product should not be taken or used under any circumstances.

Warnings and Precautions

For external use only. This product is contraindicated for application on broken skin or open wounds, as it may exacerbate irritation or lead to complications. In the event of irritation or rash, the use of this product should be discontinued immediately.

It is imperative to keep this product out of reach of children to prevent accidental ingestion or misuse. Additionally, individuals who are pregnant or breastfeeding are advised to consult a healthcare professional prior to use to ensure safety for both the mother and child.

Side Effects

Patients using this product may experience side effects. It is important to note that the product is for external use only and should not be applied to broken skin or open wounds. In the event of irritation or rash, patients are advised to discontinue use immediately.

Additionally, the product should be kept out of reach of children. Pregnant or breastfeeding individuals should consult a healthcare professional prior to use to ensure safety for both the mother and child.

Drug Interactions

There are no specific drug interactions identified for this medication. Additionally, no laboratory test interactions have been reported. Therefore, no dosage adjustments or monitoring recommendations are necessary based on the available data.

Packaging & NDC

Below are the non-prescription pack sizes of Psoriasis Scalp Treatment (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. Safety and efficacy in pediatric populations have not been established, and caution is advised when administering this medication to children.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population, given the lack of targeted data.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to use. It is essential to evaluate the potential risks and benefits of treatment during pregnancy and lactation, as the effects on fetal outcomes and nursing infants are not fully established. Healthcare providers should consider individual patient circumstances and available data when advising on the use of this medication in pregnant or breastfeeding individuals.

Lactation

Lactating mothers are advised to consult a healthcare professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating mothers.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical intervention is recommended. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and ensuring adequate circulation. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Furthermore, it is crucial to consult local poison control centers or toxicology experts for guidance on specific management protocols and antidotes, if applicable. Continuous monitoring and supportive care should be maintained until the patient is stabilized and any potential complications are addressed.

Documentation of the incident, including the substance involved, estimated dose, time of ingestion, and any symptoms observed, is vital for ongoing management and future reference.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of the reach of children to prevent accidental ingestion or misuse. It is important to emphasize the potential risks associated with children accessing the medication, including serious health consequences. Patients should be encouraged to store the medication in a secure location and to be vigilant about monitoring its use.

Storage and Handling

The product is supplied in a configuration that includes specific NDC numbers, which are essential for identification and inventory management. It is recommended to store the product in a cool, dry place to maintain its integrity and efficacy. Additionally, it is crucial to protect the product from direct sunlight to prevent any potential degradation. Proper storage conditions will ensure optimal performance and safety for healthcare professionals and patients alike.

Additional Clinical Information

Patients should apply the Folliculitis Scalp Spray to the affected area 2–3 times daily for optimal results. Clinicians should advise patients who are pregnant or breastfeeding to consult a healthcare professional prior to use. Additionally, if symptoms persist or worsen, patients are encouraged to seek guidance from a healthcare provider.

Drug Information (PDF)

This file contains official product information for Psoriasis Scalp Treatment, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)